Summit Therapeutics Raises $235M for Cancer Drug Trials - TipRanks.com

Summit Therapeutics secured $235 million in a private stock sale, selling over 10 million shares at $22.70 each, equal to the closing price. Major internal figures and biotech investors participated, indicating strong confidence. Funds will advance clinical trials for ivonescimab, an investigational cancer treatment.